Male clinical dosing
2.5–15 mg weeklyPharmaceutical dosing range
MGMT RESEARCHPRODUCT CONCEPT
METABOLIC RESEARCH
TIREZ 10 mg
Tirzepatide · Dual GIP / GLP-1 agonist
A 10 mg lyophilized research compound for investigating dual GIP / GLP-1 receptor signaling, appetite regulation, glucose metabolism, and body composition.
$80.00 CADPer vial · 10 mg option
01 / RECEPTOR PROFILEDual GIP / GLP-1 agonist
02 / QUALITYCOA pending
03 / FULFILLMENTToronto dispatch
04 / FORMATLyophilized powder
COA pending. Independent testing will be performed by SideChain Analytics in Mississauga, Ontario.
BAC Water offer +
Buy 2–5 eligible compound vials: receive one free 3 mL BAC Water. Buy 6 or more: receive one free BAC Water per eligible compound vial. Mix available compounds. AFTERBURN and RETROD Duo are excluded.
View BAC WaterTax-inclusive CAD pricing. E-transfer accepted · Credit cards coming soon.
Mix Easy · Open the calculator ↗Female clinical dosing
2.5–15 mg weeklyPharmaceutical dosing range
Clinical frequency
Once weeklyApproved pharmaceutical schedule
Clinical route
SubcutaneousPharmaceutical administration
Reported half-life
Approximately 5 daysHuman pharmacokinetic data
Post-cycle PCT
Not establishedNo validated PCT protocol
The 2.5–15 mg range describes approved pharmaceutical Tirzepatide, without separate male/female regimens. The 2.5 mg strength is an initiation dose. These are not directions for TIREZ research vials. Pharmaceutical reference ↗
DESCRIPTION
What is TIREZ 10 mg?
TIREZ is our name for Tirzepatide (LY3298176), a synthetic 39-amino-acid peptide that engages both GIP and GLP-1 receptors. Its dual incretin profile is studied in appetite regulation, glucose metabolism, and body composition research.
Your selected vial contains 10 mg of labeled lyophilized compound. This is the total vial amount, not a dose or a prepared solution concentration. MGMT Research supplies a laboratory product separate from branded prescription Tirzepatide medicines.
COA testing is pending with SideChain Analytics in Mississauga, Ontario. Batch-specific results will be added when the report is available.
BENEFITS / RESEARCH INTERESTTwo receptor targets.
Two receptor targets.
A combined metabolic profile.
Controlled Tirzepatide studies investigate body-weight reduction and metabolic outcomes. Findings concern studied pharmaceutical formulations, not promised outcomes from TIREZ.
- Appetite and body composition: weight-change endpoints in controlled trials.
- Glucose metabolism: GIP and GLP-1 signaling pathways.
- Dual agonism: comparison with selective GLP-1 receptor activity.
Product specifications & handling +
- Product
- TIREZ · Tirzepatide
- Selected quantity
- 10 mg
- Form
- Lyophilized powder
- Receptors
- GIPR · GLP-1R
- Testing
- COA pending · SideChain Analytics
- Dispatch
- Toronto, Ontario
Follow batch-specific supplier instructions and your laboratory’s validated storage and reconstitution procedures. A prepared solution’s shelf life has not been established for this product.
Orders received before 12 PM EST ship the same business day.
COA pending. Purity and net-content results will be published when the batch-specific report is available.
MIX EASYYour mixture.
Your mixture.
Made clear.
Select your compound, vial amount, diluent volume, and sample amount. Our calculator converts your inputs into a concentration, volume, and U-100 syringe marking.
01
Set your mixture
mg
mL
Enter an example amount to calculate its volume.
02
Your measurement
TIREZ
20units
0.2 mL of solution per sample
U-100 scale1 mL = 100 units
Concentration10 mg/mL
Full samples per vial5
THE CALCULATION
2 mg ÷ 10 mg/mL = 0.2 mL
How to read this calculator +
Concentration = vial amount ÷ solution volume. Sample volume = sample amount ÷ concentration. U-100 scale units = volume in mL × 100; these are volume markings, not units of compound potency.
This example assumes the final solution volume equals the diluent volume entered, and that the compound dissolves completely. It does not establish solubility, compatibility, stability, or an administration dose.
Decimal measurements are mathematical results and may fall between markings. Full samples are rounded down; they do not account for handling losses.
The calculator checks concentration mathematics. It does not select a treatment dose or establish compatibility, sterility, or stability. SEMARO is temporarily unavailable and is omitted from this selector. BAC Water is the diluent, not a peptide.
SIDE EFFECTS & CONSIDERATIONS
What the clinical data reports.
Common adverse reactions to pharmaceutical Tirzepatide include nausea, diarrhea, vomiting, constipation, abdominal discomfort, injection-site reactions, and fatigue.
Important considerations include pancreatitis, gallbladder disease, dehydration-related kidney injury, and hypoglycemia with certain glucose-lowering medicines. Thyroid C-cell tumors occurred in rats; the relevance to humans is unknown.
Product-specific considerations
- TIREZ research vials are not interchangeable with approved prescription formulations.
- A labeled 10 mg amount does not establish a therapeutic dose.
- Mixing calculations cannot establish sterility, stability, or suitability for administration.
DOSAGE GUIDELINES / CLINICAL CONTEXT
Vial amount is not a dose.
Your selected TIREZ vial is labeled 10 mg. Pharmaceutical Tirzepatide dosing does not establish a regimen for this laboratory product.
Pharmaceutical dosing range
Approved ZEPBOUND labeling describes a 2.5 mg initiation dose and 5, 10, or 15 mg maintenance doses once weekly for weight management. This summary is reference information, not instructions for TIREZ.
SURMOUNT-1 studied 5, 10, and 15 mg weekly target doses under a controlled protocol. Laboratory sample amounts and preparation procedures should come from your validated protocol.
Open Mix Easy ↗Read the pharmaceutical reference ↗